Anaplastic large cell lymphomas with the 6p25.3 rearrangement are a heterogeneous group of tumours with a diverse molecular background

• Published in: Human pathology 2023-07, Vol.137, p.71-78
• Main Authors: Díaz de la Pinta, Francisco Javier, Rodríguez Moreno, Marta, Salgado, Rocío Nieves, Carvajal García, Nerea, Santonja, Carlos, Pérez Buira, Sandra, Piris, Miguel A., Requena, Luis, Manso, Rebeca, Rodríguez-Pinilla, Socorro María
• Format: Article
• Language: English
• Subjects: 6p25.3; ALCL; ALK-negative; DUSP22; Humans; Intracellular Signaling Peptides and Proteins - genetics; Lymphoma, Large-Cell, Anaplastic - genetics; Lymphoma, Large-Cell, Anaplastic - pathology; Membrane Proteins - genetics; Proto-Oncogene Proteins c-bcl-2 - genetics; Receptor Protein-Tyrosine Kinases - genetics; RNA; t(6,7) (p25.3; q32.3); Translocation, Genetic
• ISSN: 0046-8177; 1532-8392; 1532-8392
• DOI: 10.1016/j.humpath.2023.04.015

ALK-negative anaplastic large cell lymphoma (ALCL) cases with 6p25.3 rearrangement are characterized by peculiar morphological and immunohistochemical features compare to 6p25.3-negative ALK-negative ALCL cases. A subgroup of 6p25.3-positive ALK-negative ALCL cases show the t(6,7) (p25.3;q32.3) rearrangement. Aims: To analyse the differences between 6p25.3-rearranged cases with and without t(6,7) (p25.3;q32.3). Using RNA-sequencing we studied a series of 17 samples showing 6p25.3-rearrangement, identified by FISH, consisting of seven systemic and eight primary cutaneous cases including two examples of secondary skin involvement by systemic ALCL. RNA-sequencing exclusively detected a translocation involving a gene in the 6p25.3 region (either IRF4 or DUSP22) in 7/14 cases (50%). In six of these seven cases the partner proved to be the LINC-PINT region in chromosome 7, while an EXOC2::DUSP22 rearrangement was found in one case. All cases but one were primary cutaneous ALCLs. They all were CD3 positive and BCL2 negative, while most of them expressed p-STAT3. On the contrary, cases without the t(6,7) (p25.3;q32.3) were mainly systemic (71%, 5/7) against just two pcALCL. In general, they lose CD3 (50% positive) and p-STAT3 (25% positive) expression, being all of them BCL2 positive. Moreover, in 60% of them other gene fusions were found. At the transcriptional level, they were characterized by the overexpression of TCF3 (TCF7L1/E2A), DLL3, CD58 and BCL2 genes 75%(6/8) of pcALCL with 6p25.3 rearrangement featured the so-called “biphasic morphologic pattern, which was not found in cutaneous involvement from systemic ALCL. 83% (5/6) of the pcALCL cases with the “biphasic morphologic pattern” showed the t(6,7) (p25.3;q32.3) rearrangement. ALK-negative ALCL cases with 6p25.3 rearrangement are a subgroup of tumours that are heterogeneous with respect to the presence or absence of the t(6,7) (p25.3;q32.3) translocation. •ALCL with the 6p25.3 rearrangement are a heterogeneous group of tumours.•Half of them show the t(6;7)(p25.3 ; q32.3). These cases are mainly primary cutaneous , show a biphasic morphological pattern and are BCL2-negative.•Cases without the t(6;7)(p25.3 ; q32.3) are mainly systemic and express BCL2.